Carisma Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 107
- Market Cap
- $47.7M
- Introduction
Carmanah Minerals Corp is in the exploration stage company. It engages in the exploration and development of mineral properties in Canada. The projects in which the company holds an interest are Walker Project (Uranium), Hare Hill Project (Pluton), and Loljuh Project.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Carisma Therapeutics Inc
- Target Recruit Count
- 6
- Registration Number
- NCT06254807
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
- Conditions
- HER2-positiveCarcinoma, HepatocellularLung Cancer, Non-Small-CellEsophagogastric Junction NeoplasmsInflammatory Breast CancerProstate CancerLung Cancer, Small CellBile Duct CancerCarcinoma, DuctalCancer
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Carisma Therapeutics Inc
- Target Recruit Count
- 48
- Registration Number
- NCT04660929
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
News
Carisma Therapeutics and OrthoCellix Announce $25M Merger to Advance Phase 3 Knee Cartilage Therapy
Carisma Therapeutics and OrthoCellix have entered into a definitive merger agreement to create a Nasdaq-listed regenerative cell therapy company focused on orthopedic diseases.
RNA Therapy Market Set to Reach $4.16 Billion by 2034 as Clinical Trials Accelerate
The global RNA therapy clinical trials market is projected to grow from $2.85 billion in 2024 to $4.16 billion by 2034, with a CAGR of 3.85%, driven by advancements in mRNA, siRNA, and antisense oligonucleotide-based therapies.
Resolution Therapeutics Secures $85 Million to Advance Macrophage Therapy for End-Stage Liver Disease
Resolution Therapeutics raised $85 million in Series B financing to advance RTX001, a macrophage therapy, into clinical trials for end-stage liver disease.